Last updated on August 2019

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Lymphocytic Leukemia | Lymphoma
  • Age: Between 19 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Participants administered with MabThera subcutaneously within the approved indication in Korea
  • Participants previously untreated with MabThera subcutaneously

Inclusion Criteria for NHL participants for MabThera subcutaneously 1400mg:

  • Relapsed or chemoresistant follicular lymphoma (FL) (B, C, and D type by international working formulation classification of B-cell NHL) participants
  • Previously untreated FL participants in combination with chemotherapy
  • Participants who are treated with maintenance therapy after the treatment of FL participants responding to induction therapy.
  • Cluster of differentiation 20-positive, diffuse large B-cell NHL participants in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (8 cycles) chemotherapy

Inclusion Criteria for CLL participants for MabThera subcutaneously 1600mg:

  • Previously untreated or relapsed/refractory CLL participants in combination with chemotherapy

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Participants who are out of locally approved indications, dosage, and administration including medication error
  • Contraindication in use by locally approved indications, dosage, and administration

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.